by Damon Race | Aug 29, 2023 | Press
August 29, 2023 Damon R. Race, President & CEO RALEIGH, NC – GeneVentiv Therapeutics, a pre-clinical gene therapy company focused on blood diseases and disorders, today announced that it has added Robert Baffi and Deborah Wild as Advisors as the Company prepares...
by Damon Race | Apr 12, 2023 | Press
April 12, 2023 Damon R. Race, President & CEO RALEIGH, NC – GeneVentiv Therapeutics, a pre-clinical gene therapy company focused on blood diseases and disorders, today announced it has been invited to present as part of Labcorp’s symposium at the 26th Annual...
by Damon Race | Feb 21, 2023 | Press
February 21, 2023 Damon R. Race, President & CEO RALEIGH, NC – GeneVentiv Therapeutics, a pre-clinical gene therapy company focused on blood diseases and disorders, today announced it has been invited to present new data from pre-clinical studies of its lead gene...
by Damon Race | Jan 23, 2023 | Press
January 23, 2023 Damon R. Race, President & CEO RALEIGH, NC – GeneVentiv Therapeutics, a pre-clinical gene therapy company focused on blood diseases and disorders, today announced that it has expanded the Company’s management team and board of directors with the...
by Damon Race | Jun 7, 2022 | Press
June 7, 2022 Damon R. Race, President & CEO RALEIGH, NC – GeneVentiv Therapeutics, a pre-clinical gene therapy company focused on blood diseases and disorders, today announced the award of a $250,000 Strategic Research Loan (SRL) from the North Carolina...
by Damon Race | Nov 2, 2021 | Press
Preclinical data provide quantitative evidence of GENV-HEM’s ability to achieve phenotypic correction in animal models of hemophilia, independent of the presence of any clotting factor inhibitors. Estimated 95,000 patients in the U.S. and Europe represent...
Recent Comments